文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

如何在接受CD19靶向嵌合抗原受体T细胞治疗的B细胞恶性肿瘤患者中预防感染

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
PubMed 文献 · Blood · 2020-01-01

本文为「How I Treat」类型文章,聚焦接受CD19靶向CAR-T细胞治疗患者三个阶段的感染预防关键问题:CAR-T输注前、输注后即刻和长期随访,涵盖感染病筛查、抗菌药物预防、免疫球蛋白补充、感染危险因素和疫苗接种,并指出该领域数据匮乏,旨在为各机构和医护人员提供制定各自预防策略的框架。

要点

  • CAR-T输注前需进行感染病筛查并评估患者免疫抑制状态。
  • 输注后即刻阶段需关注抗菌药物预防和感染危险因素管理。
  • 长期随访阶段需考虑免疫球蛋白补充和疫苗接种。

核心结论

  • 由于针对该治疗方式的数据匮乏,本文希望为各机构和医护人员提供框架,以制定各自的感染预防方法。

研究设计与样本

  • 本文为「How I Treat」类型文章,针对接受CD19靶向CAR-T细胞治疗的B细胞恶性肿瘤患者,按CAR-T输注前、输注后即刻和长期随访三个阶段,各以一个纵向病例引出关键问题讨论。

主要发现

  • 文章讨论了感染病筛查、抗菌药物预防、免疫球蛋白补充、感染危险因素和疫苗接种等基本问题。
  • 文章指出CAR-T输注前患者处于高度净免疫抑制状态,输注后免疫功​​能又受到独特的急性和持续性损伤。

临床怎么用

  • 文章希望为各机构和医护人员提供框架,以制定各自的感染预防方法。

局限性

  • 文章指出针对该治疗方式的数据匮乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adoptive immunotherapy using B-cell-targeted chimeric antigen receptor (CAR)-modified T cells to treat hematologic malignancies is transforming cancer care for patients with refractory or relapsed diseases. Recent and anticipated regulatory approval for products targeting acute lymphoblastic leukemia, lymphomas, and multiple myeloma have led to global implementation of these novel treatments. The rapidity of commercial utilization of CAR-T-cell therapy has created a largely unexplored gap in patient supportive-care approaches. Such approaches are critical in these complex patients given their high net state of immunosuppression prior to CAR-T-cell infusion coupled with unique acute and persistent insults to their immune function after CAR-T-cell infusion. In this "How I Treat" article, we focus on key questions that arise during 3 phases of management for patients receiving CD19-targeted CAR-T cells: pre CAR-T-cell infusion, immediate post CAR-T-cell infusion, and long-term follow-up. A longitudinal patient case is presented for each phase to highlight fundamental issues including infectious diseases screening, antimicrobial prophylaxis, immunoglobulin supplementation, risk factors for infection, and vaccination. We hope this discussion will provide a framework for institutions and health care providers to formulate their own approach to preventing infections in light of the paucity of data specific to this treatment modality.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020. PMID: 32582924. doi:10.1182/blood.2019004000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。